Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Tofacitinib vs Methotrexate in the Treatment of Psoriatic Arthritis
TCTR20181205001Phase 3Recruiting
- Sponsor
- Globe Pharmaceuticals
- Start
- Nov 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tofacitinib, methotrexate in psoriatic arthritis (PsA), sponsored by Globe Pharmaceuticals. Started Nov 2018; status: recruiting.
02
Drugs
tofacitinibmethotrexate
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on TCTR20181205001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20181205001.